W. Michael F. Flanagan
Independent DirectorDr. W. Michael F. Flanagan, Ph.D also known as Mike, is Independent Director of Atrium Therapeutics, Inc. since February 2026. Dr. Flanagan served as Chief Scientific Officer and has led Research at Avidity since January 2025 until February 27, 2026 and previously served as Chief Scientific and Technology Officer at Avidity, where he led both Research and Manufacturing from February 2023 to January 2025. He previously served as the Chief Technology Officer of Avidity from January 2021 to February 2023. Dr. Flanagan has extensive experience developing multiple therapeutic modalities, including RNA therapeutics, antibody drug conjugates and bispecific antibodies. Prior to his time at Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc. from January 2012 to January 2021, where he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, Dr. Flanagan served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc. (Nasdaq: GILD) and Merck & Co. Inc. (NYSE: MRK), where he was Senior Director of RNA Sciences. Dr. Flanagan received a B.S. in Genetics from the University of California at Davis, a Ph.D. in Biological Sciences from the University of California at Irvine and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford School of Medicine. We believe Dr. Flanagan is qualified to serve on the Board of Directors because he is a proven biotechnology executive, recognized for his deep scientific and operational expertise, with more than 25 years of experience advancing first-in-class therapeutics, scaling innovative companies across RNA, oncology and immunology and leading organizations through major milestones (including platform creation, clinical advancement, capital formation, partnerships and acquisitions).
Positions
- Company NameAtrium Therapeutics, Inc.Stock CodeRNAPositionIndependent DirectorColleagues
- KPKathleen P. GallagherPresident, CEO & Director
- SBSarah BoyceIndependent Chair of the Board of Director
- BWBrendan WinslowChief Financial Officer
- HYHusam YounisChief Scientific Officer
- SKStephanie KenneyChief Corporate Affairs Officer
- SGSteven George HughesChief Medical Officer
- CBCarsten BoessIndependent Director
- TETroy Edward WilsonIndependent Director
